VEGF

114개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved114 programs
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Bevacizumab, RHUMAB VEGF (Avastin, Avastin (Bevacizumab, RHUMAB VEGF))

Rectal Cancer · Rectal Cancer

#RectalCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 1

bevacizumab, reference product (Avastin®, Avastin® (bevacizumab, reference product))

Metastatic Colorectal Cancer (mCRC) · Metastatic Colorectal Cancer (mCRC)

#MetastaticColorectalCancermCRC#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#NSCLCStageIVWithoutEGFR+2
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

ranibizumab (Lucentis, Bevacizumab, Ranibizumab)

Retinopathy of Prematurity Both Eyes · Retinopathy of Prematurity Both Eyes

#RetinopathyofPrematurityBothEyes#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleProgen PharmaceuticalsPhase 1

CGC-11047 and bevacizumab (CGC-11047 and bevacizumab)

Cancer · Cancer

#Cancer#Antibody#Phase1#monoclonal-antibody#Progen
Trials 1Status Active
AntibodyLimited DatastaleCaigang LiuPhase 3

Cadonilimab (AK104, Cadonilimab, Cadonilimab (AK104) combined with chemotherapy and bevacizumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#monoclonal-antibody#Caigang
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab and Bevacizumab (Camrelizumab and Bevacizumab)

Recurrent Glioblastoma · Recurrent Glioblastoma

#RecurrentGlioblastoma#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Discontinued
AntibodyLimited DatastaleSouth Eastern European Research…Phase 2

Capecitabine and Bevacizumab (Capecitabine and Bevacizumab)

Breast Cancer; Metastasis · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Metastasis+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Capecitabine plus bevacizumab (Capecitabine plus bevacizumab)

Elderly Patients; Metastatic Colorectal Cancer · Elderly Patients

#ElderlyPatients#Antibody#Phase3#monoclonal-antibody#MetastaticColorectalCancer+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePreclinical

Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors (Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors)

Colorectal Cancer Metastatic · PD-1

#PD-1#Antibody#Preclinical#monoclonal-antibody#ColorectalCancerMetastatic+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Cryoablation Combined with Tirelizumab and Bevacizumab (Cryoablation Combined with Tirelizumab and Bevacizumab)

Metastatic Breast Cancer in the Liver · Metastatic Breast Cancer in the Liver

#MetastaticBreastCancerintheLiver#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPreclinical

DEBIRI Combined With Chemotherapy and Bevacizumab (DEBIRI Combined With Chemotherapy and Bevacizumab)

Colorectal Neoplasms · Colorectal Neoplasms

#ColorectalNeoplasms#Antibody#Preclinical#monoclonal-antibody#Fudan
Trials 1Status Active
AntibodyLimited DatastaleDizal PharmaceuticalsPhase 2

DZD9008 plus Bevacizumab (DZD9008 plus Bevacizumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Dizal
Trials 1Status Recruiting
AntibodyLimited DatastaleCedars-Sinai Medical CenterPhase 1

Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab (Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#Antibody#Phase1#monoclonal-antibody#GlioblastomaMultiforme+1
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin + tislelizumab + bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
AntibodyLimited DatastaleSanofiPhase 2

Docetaxel (Docetaxel, Docetaxel (T) + bevacizumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Sanofi
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1/PD-L1 CAR-T cells (Dual-targeting VEGFR1/PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

2 / 6 pages

← PreviousNext →